Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

FAXAge protocol: fasting and exercise tested against aging clocks in adults 65+

This protocol plans a 52-week randomized trial in 240 healthy adults aged 65 and above, comparing combined cardio and strength training, time-restricted feeding, both together, or control, with DNA methylation aging pace as the primary outcome. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The protocol plans to allocate 240 healthy adults aged 65 and above to four groups: combined cardio and strength training, time-restricted feeding, both together, or control. [1]

  2. The primary outcome is Dunedin Pace of Aging DNA methylation age, with secondary measures including RNA-sequencing, metabolomics, inflammatory markers, microbiome analysis, and cognitive and physical measures. [1]

  3. The authors state the study will provide insights into whether time-restricted feeding, exercise, or a combination can slow or reverse biological aging in older adults. [1]

The source at a glance

Study type / format
Study protocol for a randomized controlled trial
Population / context
240 healthy adults aged 65 and above (planned).
Summary based on
Study abstract
Original publication
June 29, 2026

Planned four-arm trial in adults 65 and older

The FAXAge protocol describes a 52-week four-armed randomized controlled trial (NCT07207044). It plans to allocate 240 healthy adults aged 65 and above to four groups: combined cardio and strength training (EXE), time-restricted feeding (TRF), combined EXE and TRF, or control. Assessments are planned at baseline, 3, 6 and 12 months, with follow-ups at 2, 5 and 10 years. The authors note that the combined effect of exercise and TRF on aging biomarkers remains largely unexplored.

Supporting source [1]

Primary outcome is DNA methylation aging pace

The primary outcome measure is the Dunedin Pace of Aging DNA methylation age. Secondary measures include RNA-sequencing, metabolomics, inflammatory markers, microbiome analysis, and cognitive and physical measures. The protocol states that DNA methylation-based clocks have shown promise as tools to assess whether interventions may impact the rate of biological aging. It also notes that exercise has shown protective effects against many age-associated diseases, while TRF has shown metabolic benefits in preclinical models.

Supporting source [1]

Protocol only: no results yet reported

This is a study protocol, so it reports planned design rather than outcomes. The abstract does not report whether any intervention slowed or reversed biological aging; the authors say the study will provide insights into whether TRF, EXE, or a combination can slow or reverse biological aging in older adults. The abstract was reviewed; the full text was not reviewed.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is a study protocol, so no results on aging outcomes are reported.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Study protocol for FAXAge: a randomized, controlled clinical trial of fasting and exercise to slow aging in humans.

Fals EB, Springborg EC, Berthelsen AB, Nyeman-Nielsen J, Larsen S, Scheibye-Knudsen M. · europepmc.org · June 29, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    240 healthy adults aged 65 and above
  2. Finding 2 ↑

    The primary outcome measure is Dunedin Pace
  3. Finding 3 ↑

    can slow or reverse biological aging in

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…